Publications by authors named "C Gerard"
Background: Metastatic uveal melanoma (mUM) is rare. Immune checkpoint inhibitors (ICIs) have shown modest efficacy in mUM. Tebentafusp prolonged overall survival (OS) in a phase 3 study.
View Article and Find Full Text PDFAim: The study explored whether the reported experience of primary healthcare differs for survey respondents in Aotearoa New Zealand who self-report having a mental health (MH) condition in comparison with those who do not.
Method: Responses to the New Zealand Health Quality & Safety Commission's adult primary care patient experience survey received from August 2020 to May 2022 were analysed. Comparative analysis of patient-reported experience measures were completed to contrast experiences reported by those with and without a MH condition, with results stratified by ethnicity (Māori/non-Māori), age group and gender.
Article Synopsis
- - The French Society of Rheumatology and the French Society of Physical Medicine and Rehabilitation aimed to create recommendations for non-drug treatments for knee osteoarthritis due to their inadequate consideration in care.
- - A systematic review of literature was conducted, followed by discussions among experts to draft and evaluate a list of recommendations for managing knee OA non-pharmacologically.
- - Five key principles were established, emphasizing a combination of treatments, personalized management, adherence, appropriate exercise, and education, alongside specific recommendations for 11 modalities like braces, physical therapy, and weight loss.
Standardized Reasons for Consultations on a French Telemedicine Platform.
Stud Health Technol Inform
August 2024
Thirteen standardized reasons for e-visits were implemented in March 2024 on a French telemedicine platform to improve the analysis of needs in telemedicine, educate patients on what is possible in e-visit and adapt the offer. Patients could select 1 to 3 reasons for consultations among a list of 13 reasons. Our aim was to evaluate their impact on use of e-visits.
View Article and Find Full Text PDFIntroduction: Respiratory syncytial virus (RSV) and influenza pose major disease burdens in older adults due to an aging immune system and comorbidities; seasonal overlap exists between these infections. In 2023, the RSV prefusion protein F3 older adult (RSVPreF3 OA) vaccine was first approved in the USA as a single dose for prevention of lower respiratory tract disease due to RSV in adults aged ≥ 60 years. The vaccine has since been approved in the European Union and elsewhere.
View Article and Find Full Text PDF